0000905718-17-000626.txt : 20170626
0000905718-17-000626.hdr.sgml : 20170626
20170626163913
ACCESSION NUMBER: 0000905718-17-000626
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170622
FILED AS OF DATE: 20170626
DATE AS OF CHANGE: 20170626
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CRISPR Therapeutics AG
CENTRAL INDEX KEY: 0001674416
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 473173478
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: AESCHENVORSTADT 36
CITY: BASEL
STATE: V8
ZIP: 4051
BUSINESS PHONE: 6173154600
MAIL ADDRESS:
STREET 1: AESCHENVORSTADT 36
CITY: BASEL
STATE: V8
ZIP: 4051
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: EMSTER KURT VON
CENTRAL INDEX KEY: 0001252524
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37923
FILM NUMBER: 17930236
MAIL ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD
STREET 2: SUITE 350
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
vonemster_form4jun222017.xml
OWNERSHIP DOCUMENT
X0306
4
2017-06-22
0
0001674416
CRISPR Therapeutics AG
CRSP
0001252524
EMSTER KURT VON
C/O CRISPR THERAPEUTICS, INC.
200 SIDNEY STREET
CAMBRIDGE
MA
02139
1
0
0
0
Common Shares
2017-06-22
4
S
0
1527
16.21
D
2600287
I
See Footnote
Common Shares
2017-06-23
4
S
0
30841
16.23
D
2569446
I
See Footnote
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP ("Abingworth") on May 15, 2017.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.20 to $16.24 per share, inclusive. Kurt von Emster (the "Reporting Person") undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
These shares are held by Abingworth. Abingworth Bioventures VI GP LP ("Abingworth GP") serves as the general partner of Abingworth. Abingworth General Partner VI LLP, serves as the general partner of Abingworth GP. Abingworth (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by Abingworth. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The reporting person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.20 to $16.69 per share, inclusive. Reporting Person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein
/s/ Kurt von Emster
2017-06-26